Payment overview · 2025
General Payments
$1,773.46
86 reported records · 23 companies
Healthcare provider profile · identity verified
Maray Rocher, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1306022819
Verified facts
What the public records show
CMS Open Payments records show Maray Rocher, M.D received $1,773.46 in general payments during 2025 across 86 reported records.
Amgen Inc. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 556 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $243.62 | 13.7% | 19 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $222.23 | 12.5% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.71 | 12.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.17 | 7.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $134.75 | 7.6% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $112.56 | 6.3% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $98.65 | 5.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.55 | 5.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $59.59 | 3.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.63 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.98 | 3.0% | 3 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $41.76 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.59 | 2.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.11 | 1.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $33.24 | 1.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.13 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.95 | 1.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.07 | 1.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $26.54 | 1.5% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.36 | 1.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.71 | 1.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.11 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.45 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,773.46 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $172.13 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $147.38 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.17 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $119.15 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $116.10 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.68 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $112.56 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $112.30 | 10 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $98.65 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $89.55 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.03 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $65.01 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.59 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $56.63 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $41.76 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $41.76 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.95 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 556 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 261 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 248 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 165 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 165 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
248 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
261 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
165 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
165 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
201 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
556 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1087 | 248 |
| Gabapentin | Gabapentin | 771 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 741 | 117 |
| Omeprazole | Omeprazole | 721 | 126 |
| Famotidine | Famotidine | 652 | 125 |
| Losartan Potassium | Losartan Potassium | 596 | 124 |
| Eliquis | Apixaban | 556 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 525 | 100 |
| Furosemide | Furosemide | 523 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 515 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 98 |
| Metformin Hcl | Metformin Hcl | 494 | 90 |
| Montelukast Sodium | Montelukast Sodium | 484 | 89 |
| Carvedilol | Carvedilol | 473 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 457 | 86 |
| Trazodone Hcl | Trazodone Hcl | 436 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 383 | 81 |
| Lisinopril | Lisinopril | 348 | 64 |
| Diclofenac Sodium | Diclofenac Sodium | 344 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 329 | 71 |
| Memantine Hcl | Memantine Hcl | 327 | 57 |
| Ketoconazole | Ketoconazole | 306 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 290 | 59 |
| Fenofibrate | Fenofibrate Nanocrystallized | 289 | 58 |
| Sertraline Hcl | Sertraline Hcl | 265 | 56 |
| Farxiga | Dapagliflozin Propanediol | 261 | 47 |
| Meclizine Hcl | Meclizine Hcl | 251 | 43 |
| Linzess | Linaclotide | 248 | 39 |
| Clonazepam | Clonazepam | 238 | 41 |
| Donepezil Hcl | Donepezil Hcl | 231 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 231 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 49 |
| Ibuprofen | Ibuprofen | 221 | 50 |
| Azithromycin | Azithromycin | 216 | 152 |
| Alendronate Sodium | Alendronate Sodium | 213 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 213 | 34 |
| Alprazolam | Alprazolam | 212 | 37 |
| Mirtazapine | Mirtazapine | 203 | 49 |
| Xarelto | Rivaroxaban | 203 | 46 |
| Entresto | Sacubitril/Valsartan | 201 | 37 |
| Ammonium Lactate | Ammonium Lactate | 198 | 29 |
| Buspirone Hcl | Buspirone Hcl | 179 | 40 |
| Allopurinol | Allopurinol | 175 | 26 |
| Glipizide | Glipizide | 166 | 29 |
| Repatha Sureclick | Evolocumab | 166 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 166 | 32 |
| Mounjaro | Tirzepatide | 165 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 165 | 27 |
| Sucralfate | Sucralfate | 157 | 30 |
| Valsartan | Valsartan | 157 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 24 |
| Levetiracetam | Levetiracetam | 151 | 32 |
| Ozempic | Semaglutide | 149 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 32 |
| Nifedipine Er | Nifedipine | 146 | 31 |
| Diclofenac Sodium Er | Diclofenac Sodium | 141 | 33 |
| Nystatin | Nystatin | 140 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 30 |
| Meloxicam | Meloxicam | 126 | 27 |
| Celecoxib | Celecoxib | 125 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 20 |
| Simvastatin | Simvastatin | 119 | 21 |
| Potassium Chloride | Potassium Chloride | 118 | 25 |
| Baclofen | Baclofen | 117 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 21 |
| Pregabalin | Pregabalin | 115 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 35 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 111 | 15 |
| Mupirocin | Mupirocin | 110 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 109 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 109 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 100 | 21 |
| Folic Acid | Folic Acid | 94 | 27 |
| Lactulose | Lactulose | 94 | 21 |
| Latanoprost | Latanoprost | 94 | 15 |
| Bumetanide | Bumetanide | 93 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 27 |
| Levofloxacin | Levofloxacin | 92 | 68 |
| Ciclopirox | Ciclopirox | 91 | 22 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 89 | 16 |
| Glyxambi | Empagliflozin/Linagliptin | 89 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 89 | 17 |
| Hydrocortisone | Hydrocortisone | 88 | 16 |
| Ssd | Silver Sulfadiazine | 88 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 85 | 24 |
| Clotrimazole | Clotrimazole | 84 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 18 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 82 | 24 |
| Finasteride | Finasteride | 82 | 18 |
| Clonidine Hcl | Clonidine Hcl | 80 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 79 | 12 |
| Glipizide Er | Glipizide | 79 | 13 |
| Trulicity | Dulaglutide | 79 | 12 |
| Lorazepam | Lorazepam | 78 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 77 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 17 |
| Vascepa | Icosapent Ethyl | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 12 |
| Januvia | Sitagliptin Phosphate | 73 | 13 |
| Olanzapine | Olanzapine | 72 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 72 | 20 |
| Temazepam | Temazepam | 72 | 17 |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 57 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | suppressed |
| Spironolactone | Spironolactone | 69 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 67 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 66 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 23 |
| Novolog Flexpen | Insulin Aspart | 64 | 11 |
| Azelastine Hcl | Azelastine Hcl | 63 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 63 | suppressed |
| Metronidazole | Metronidazole | 62 | 36 |
| Synthroid | Levothyroxine Sodium | 62 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 61 | 11 |
| Atenolol | Atenolol | 60 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 12 |
| Rexulti | Brexpiprazole | 59 | 12 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Ingrezza | Valbenazine Tosylate | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 42 |
| Telmisartan | Telmisartan | 54 | suppressed |
| Brilinta | Ticagrelor | 50 | 15 |
| Budesonide | Budesonide | 49 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 11 |
| Risperidone | Risperidone | 49 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 49 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 39 |
| Digoxin | Digoxin | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 39 |
| Naproxen | Naproxen | 46 | 13 |
| Methocarbamol | Methocarbamol | 45 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 25 |
| Tramadol Hcl | Tramadol Hcl | 45 | 22 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 45 | 11 |
| Jardiance | Empagliflozin | 43 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Prednisone | Prednisone | 41 | 20 |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 38 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Nystop | Nystatin | 39 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 38 | 11 |
| Megestrol Acetate | Megestrol Acetate | 38 | 19 |
| Restasis | Cyclosporine | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | 17 |
| Dexamethasone | Dexamethasone | 35 | 29 |
| Metolazone | Metolazone | 35 | 12 |
| Mometasone Furoate | Mometasone Furoate | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 13 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Nyamyc | Nystatin | 32 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Cyclosporine | Cyclosporine | 31 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Desloratadine | Desloratadine | 30 | suppressed |
| Levemir | Insulin Detemir | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Pentoxifylline | Pentoxifylline | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 12 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 28 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Tadalafil | Tadalafil | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Prolia | Denosumab | 23 | 14 |
| Topiramate | Topiramate | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Epinephrine | Epinephrine | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 14 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Silodosin | Silodosin | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 17 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 16 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Edurant | Rilpivirine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 14 |
| Repaglinide | Repaglinide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,773.46 · 86 records | Amgen Inc. | AIRSUPRA, AREXVY, CREON, DOVATO, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, NUZYRA, Natroba, OCALIVA, OTEZLA, Ozempic, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, Spinosad, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error